Exosome-peptide conjugates
Cell-derived nanovesicles loaded with or displaying regenerative peptides, used to get cargo across barriers that free peptides cannot cross — scientifically real, commercially a swamp.
Also known as peptide-loaded exosomes, EV peptide delivery, extracellular vesicle conjugates
Animal data only — Rodent or other animal studies. Dose translation to humans is genuinely uncertain.
The engineering literature is legitimate and growing, with convincing rodent data for targeted delivery including across the blood-brain barrier. Human evidence for any commercial exosome-peptide product is essentially absent, and the aesthetics-clinic market operates entirely outside regulatory oversight with documented harm. The gap between the science and the storefront is wider here than anywhere else in this class.
How it works
Exosomes are 30-150 nm vesicles of endosomal origin that carry protein, lipid and RNA cargo between cells and are taken up by recipient cells through endocytosis and membrane fusion. Two distinct things are marketed under this heading. The first is genuine engineering: loading a therapeutic peptide inside the vesicle by electroporation, sonication or by fusing it to a vesicle-resident protein such as Lamp2b, and displaying a targeting peptide such as RVG or an integrin-binding motif on the surface to direct biodistribution. This has produced credible rodent data for CNS delivery, cartilage penetration and tumour targeting. The second is the aesthetics and regenerative-clinic market, where 'exosome' typically means an uncharacterised conditioned-medium or placental-derived preparation with no vesicle quantification, no cargo characterisation and no sterility assurance — the FDA has issued repeated warnings and there have been documented bacterial infection outbreaks from unapproved exosome injections. Both use the same word.
Targets: Delivery vehicle - target depends entirely on cargo and surface-display peptide
Dosing
| Protocol | Dose | Frequency | Route |
|---|---|---|---|
| No validated human protocolNot applicable. | — | not established | intravenous |
- · Clinic protocols quote doses in 'particles' or 'billions of exosomes', a unit with no standardised measurement method across suppliers. There is no validated human dose for any engineered exosome-peptide product, and the numbers on a clinic's price list are marketing, not pharmacology.
Cycling
Not established.
Pharmacology
- Half-life
- Circulating exosomes are cleared by liver and spleen within minutes to a few hours; surface engineering with CD47 or PEG extends this modestly.
- Onset
- Not defined; entirely dependent on cargo.
- Routes
- intravenous, subcutaneous, topical, intramuscular
- Molecule
- Lipid bilayer extracellular vesicles (30-150 nm) carrying peptide cargo or surface-displayed targeting peptides
Handling
- Diluent
- Not applicable
- Lyophilised
- Not applicable — most preparations are stored frozen at -80 C as suspensions.
- Reconstituted
- Use immediately after thawing; vesicle integrity degrades quickly.
Mixing
Supplied frozen as a suspension, not as a lyophilised peptide. Freeze-thaw destroys vesicle integrity, and there is no practical way for an end user to verify that intact vesicles are present.
Side effects
- commonInjection-site reaction
- uncommonBacterial infection and sepsis— Not theoretical — the CDC documented an outbreak of bacterial infections in patients who received unapproved exosome products at a clinic. Biological products from unregulated manufacturers can be contaminated.
- uncommonImmune reaction to allogeneic material— These are cell-derived products carrying donor surface proteins.
Do not use if
- Active malignancy - exosomes carry pro-angiogenic and pro-proliferative cargo and tumour-derived vesicle biology is a well-documented driver of metastasis.
- Immunocompromised state - the contamination risk from unregulated biological products is the dominant danger here.
- Any product from a supplier who cannot provide sterility testing and particle characterisation.
What to monitor
- · If someone proceeds anyway: temperature, injection site and any systemic infectious signs in the 72 hours afterward. This is an infection-risk product before it is a pharmacology product.
Legal status
No exosome product is FDA-approved for any indication. The FDA has issued public safety notifications about unapproved exosome products marketed by clinics.
References
- Kalluri & LeBleu 2020, Science — the biology, function and biomedical applications of exosomes (review)
- FDA public safety notification on unapproved exosome products (guideline)
Mechanism in depth
Loading or displaying peptides on extracellular vesicles, on the rationale that exosomes have natural tropism, cross barriers that free peptides cannot, and protect cargo from degradation. Attractive in principle for central nervous system delivery in particular.
What usually goes wrong
The field's central unsolved problems are characterisation and consistency: exosome preparations are heterogeneous, potency assays are not standardised, and 'exosome' in a commercial product frequently describes something that has not been shown to be exosomes at all. Unregulated exosome products have already drawn regulatory warnings and caused serious infections in clinics.
Receptor targets
- Determined by vesicle surface and any targeting ligand
Delivery strategy rather than a mechanism of action
Genuinely uncertain
- No approved exosome therapeutic exists.
- Characterisation and batch consistency remain unsolved.
- Commercial products sold under this label are frequently unverified.